Cargando…
1359. Activity of Meropenem/Nacubactam Combination Against Gram-Negative Clinical Isolates: ROSCO Global Surveillance 2017
BACKGROUND: Nacubactam (NAC, OP0595, RG6080) is a novel member of the diazabicyclooctane inhibitor family with a dual mode of action, acting as a β-lactamase inhibitor and an antibacterial agent by means of PBP2 inactivation. NAC restores and extends the activity of β-lactam antibiotics, such as mer...
Autores principales: | Okujava, Rusudan, Garcia-Alcalde, Fernando, Haldimann, Andreas, Zampaloni, Claudia, Morrissey, Ian, Magnet, Sophie, Kothari, Nimmi, Harding, Ian, Bradley, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252560/ http://dx.doi.org/10.1093/ofid/ofy210.1190 |
Ejemplares similares
-
1368. Assessment of the In Vivo Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β-Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model
por: Asempa, Tomefa E, et al.
Publicado: (2018) -
Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers
por: Mallalieu, Navita L., et al.
Publicado: (2020) -
698. Nacubactam Inhibits Class A β-lactamases
por: Barnes, Melissa D, et al.
Publicado: (2018) -
2131. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against Clinical Acinetobacter Isolates from China
por: Hawser, Stephen, et al.
Publicado: (2023) -
In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014–2015
por: Morrissey, Ian, et al.
Publicado: (2019)